Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Odyssey Therapeutics, Inc.ODTX · Entity 4850 | Director | May 07, 2026 | May 12, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, Chief Reg. & Quality Off. | July 21, 2026 | July 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Odyssey Therapeutics, Inc.
Report date May 07, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-05-06 | Direct | 27,393 |
Reported balance
After 2026-05-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-07 · Grant · Acquired 27,393 · Balance 27,393 F1: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date.
VERTEX PHARMACEUTICALS INC / MA
Report date July 21, 2026 · Filed July 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,572 |
Reported balance
After 2026-07-21 transaction · row 1
1 source rowRow 1 · 2026-07-21 · Grant · Acquired 8,251 · Balance 53,572 F1: Restricted stock unit award that vests on 03/31/2030. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock unit award that vests on 03/31/2030.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Verve Therapeutics, Inc.
Report date July 25, 2025 · Filed July 28, 2025
Section 16 reporting ended · disclosed 2025-07-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.02 | Direct | 0 |
Reported balance
After 2025-07-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-25 · Disposition to issuer · Disposed 267,541 · Balance 0 F1: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the F2: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.73 | Direct | 0 |
Reported balance
After 2025-07-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-07-25 · Disposition to issuer · Disposed 42,200 · Balance 0 F1: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the F2: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the
F2: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2023 Filed Feb 28, 2023 22:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 20 | $289.29 | $5,785.80 |
DisclosureSEC source: 0001209191-23-013765 · doc4.xml · nonDerivative · entry 4 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,805 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $289.29 (range $289.17 to $289.40). Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 22:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 51 | $288.33 | $14,704.83 |
DisclosureSEC source: 0001209191-23-013765 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,825 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $288.33 (range $287.82 to $288.74). Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 22:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 283 | $287.20 | $81,277.60 |
DisclosureSEC source: 0001209191-23-013765 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,876 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $287.20 (range $286.71 to $287.60). Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 22:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,308 | $289.12 | $956,408.96 |
DisclosureSEC source: 0001209191-23-013765 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,159 Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 124 | $294.77 | $36,551.48 |
DisclosureSEC source: 0001209191-23-011704 · doc4.xml · nonDerivative · entry 5 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,467 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $294.77 (range $294.42 to $295.37). Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 207 | $293.83 | $60,822.81 |
DisclosureSEC source: 0001209191-23-011704 · doc4.xml · nonDerivative · entry 4 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,591 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $293.83 (range $293.39 to $294.38). Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 145 | $292.85 | $42,463.25 |
DisclosureSEC source: 0001209191-23-011704 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,798 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $292.85 (range $292.37 to $293.36). Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4 | $291.01 | $1,164.04 |
DisclosureSEC source: 0001209191-23-011704 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,943 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 4,498 | $292.85 | $1,317,239.30 |
DisclosureSEC source: 0001209191-23-011704 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,947 Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 51 | $300.58 | $15,329.58 |
DisclosureSEC source: 0001209191-23-010061 · doc4.xml · nonDerivative · entry 5 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,445 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $300.58 (range $300.34 to $301.01). Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 135 | $299.60 | $40,446.00 |
DisclosureSEC source: 0001209191-23-010061 · doc4.xml · nonDerivative · entry 4 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,496 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $299.60 (range $299.19 to $300.16). Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 43 | $297.98 | $12,813.14 |
DisclosureSEC source: 0001209191-23-010061 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,631 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $297.98 (range $297.50 to $298.48). Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 20 | $296.48 | $5,929.60 |
DisclosureSEC source: 0001209191-23-010061 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,674 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 71 | $295.89 | $21,008.19 |
DisclosureSEC source: 0001209191-23-010061 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,694 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $295.89 (range $295.36 to $296.32). Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 22:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 11 | $300.79 | $3,308.69 |
DisclosureSEC source: 0001209191-23-009237 · doc4.xml · nonDerivative · entry 7 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,765 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 22:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 64 | $299.88 | $19,192.32 |
DisclosureSEC source: 0001209191-23-009237 · doc4.xml · nonDerivative · entry 6 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,776 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $299.88 (range $299.62 to $300.53). Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 22:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 120 | $298.98 | $35,877.60 |
DisclosureSEC source: 0001209191-23-009237 · doc4.xml · nonDerivative · entry 5 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,840 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $298.98 (range $298.53 to $299.50). Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 22:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 78 | $298.11 | $23,252.58 |
DisclosureSEC source: 0001209191-23-009237 · doc4.xml · nonDerivative · entry 4 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,960 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $298.11 (range $297.51 to $298.50). Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 22:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2 | $295.84 | $591.68 |
DisclosureSEC source: 0001209191-23-009237 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,038 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 22:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,995 | $298.26 | $893,288.70 |
DisclosureSEC source: 0001209191-23-009237 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,040 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 1,377 | $294.33 | $405,292.41 |
DisclosureSEC source: 0001209191-23-009237 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,035 Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 7,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006996 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,412 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/10/2024. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,262 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006996 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,546 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 6,194 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006996 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,284 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 74 | $301.67 | $22,323.58 |
DisclosureSEC source: 0000899243-22-028248 · doc4.xml · nonDerivative · entry 5 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,090 F2 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 72 | $300.64 | $21,646.08 |
DisclosureSEC source: 0000899243-22-028248 · doc4.xml · nonDerivative · entry 4 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,164 F2 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 283 | $299.79 | $84,840.57 |
DisclosureSEC source: 0000899243-22-028248 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,236 F2 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $299.79 (range $299.44 to $300.33). Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 679 | $298.77 | $202,864.83 |
DisclosureSEC source: 0000899243-22-028248 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,519 F2 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $298.77 (range $298.29 to $299.19). Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 292 | $297.54 | $86,881.68 |
DisclosureSEC source: 0000899243-22-028248 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,198 F2 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $297.54 (range $297.00 to $297.80). F1 · balance_after: Includes 134 shares previously purchased under the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 34 | $251.24 | $8,542.16 |
DisclosureSEC source: 0000899243-22-011705 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,356 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,799 | $250.10 | $700,029.90 |
DisclosureSEC source: 0000899243-22-011705 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,390 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $250.10 (range $250.00 to $250.55). F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 22:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 18 | $232.80 | $4,190.40 |
DisclosureSEC source: 0000899243-22-008123 · doc4.xml · nonDerivative · entry 6 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,189 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $232.80 (range $232.59 to $232.92). Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 22:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 87 | $231.81 | $20,167.47 |
DisclosureSEC source: 0000899243-22-008123 · doc4.xml · nonDerivative · entry 5 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,207 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $231.81 (range $231.52 to $232.31). Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 22:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 115 | $230.97 | $26,561.55 |
DisclosureSEC source: 0000899243-22-008123 · doc4.xml · nonDerivative · entry 4 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,294 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $230.97 (range $230.50 to $231.47). Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 22:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 77 | $230.26 | $17,730.02 |
DisclosureSEC source: 0000899243-22-008123 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,409 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $230.26 (range $229.50 to $230.48). Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 22:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 28 | $228.88 | $6,408.64 |
DisclosureSEC source: 0000899243-22-008123 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,486 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $228.88 (range $228.39 to $229.36). F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 22:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,590 | $227.86 | $590,157.40 |
DisclosureSEC source: 0000899243-22-008123 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,514 Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 22:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 120 | $233.48 | $28,017.60 |
DisclosureSEC source: 0000899243-22-007216 · doc4.xml · nonDerivative · entry 5 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,104 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $233.48 (range $233.18 to $233.73). Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 22:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 80 | $232.04 | $18,563.20 |
DisclosureSEC source: 0000899243-22-007216 · doc4.xml · nonDerivative · entry 4 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,224 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $232.04 (range $231.89 to $232.13). Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 22:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 101 | $230.42 | $23,272.42 |
DisclosureSEC source: 0000899243-22-007216 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,304 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $230.42 (range $230.05 to $230.75). Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 22:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 218 | $229.52 | $50,035.36 |
DisclosureSEC source: 0000899243-22-007216 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,405 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $229.52 (range $229.05 to $229.97). F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 4,114 | $232.51 | $956,546.14 |
DisclosureSEC source: 0000899243-22-007216 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,623 Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 21:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 42 | $236.85 | $9,947.70 |
DisclosureSEC source: 0001209191-22-009249 · doc4.xml · nonDerivative · entry 5 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,737 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $236.85 (range $236.84 to $236.87). Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 21:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 70 | $235.87 | $16,510.90 |
DisclosureSEC source: 0001209191-22-009249 · doc4.xml · nonDerivative · entry 4 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,779 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $235.87 (range $235.41 to $236.08). Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 21:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 78 | $234.93 | $18,324.54 |
DisclosureSEC source: 0001209191-22-009249 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,849 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $234.93 (range $234.28 to $235.25). Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 21:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $233.92 | $23,392.00 |
DisclosureSEC source: 0001209191-22-009249 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,927 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $233.92 (range $233.26 to $234.24). F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 1,230 | $237.74 | $292,420.20 |
DisclosureSEC source: 0001209191-22-009249 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,027 Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,262 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006794 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,257 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2023. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 13,952 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006794 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,995 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006794 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,043 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.